| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T403 |
0-26 |
Sentence |
denotes |
Clinical Research on SFJDC |
| T404 |
27-155 |
Sentence |
denotes |
SFJDC comes from “Detoxification Powder,” and is mainly used to treat fever, parotitis, amygdalitis, plague, and other diseases. |
| T405 |
156-398 |
Sentence |
denotes |
Recent studies have shown that SFJDC has good clinical efficacy against viral diseases (such as MERS, influenza, human infection with H7N9 avian influenza) and respiratory diseases (such as acute URI, AECOPD, pneumonia, etc.) (see Table 3 ). |
| T406 |
399-685 |
Sentence |
denotes |
SFJDC has been recommended in diagnosis and treatment schemes such as MERS Diagnosis and Treatment Scheme (Version 2015), China’s Influenza Diagnosis and Treatment Scheme (Version 2019), and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017). |
| T407 |
686-898 |
Sentence |
denotes |
Lei Wang et al. conducted a retrospective analysis of 87 patients with acute URI + fever, and found that patients treated with SFJDC had a significantly higher total response rate than those in the control group. |
| T408 |
899-1003 |
Sentence |
denotes |
SFJDC effectively improved respiratory symptoms in patients with acute URI + fever (Wang and Qiu, 2018). |
| T409 |
1004-1275 |
Sentence |
denotes |
In the treatment of community acquired pneumonia (CAP), application of SFJDC shortened recovery time, reduced the duration of fever and reduced the levels of procalcitonin (PCT), CRP, WBC, and other indicators, effectively shortening the course of treatment (Wang, 2016). |
| T410 |
1276-1385 |
Sentence |
denotes |
Hongxia Yu et al. evaluated the impact of SFJDC on inflammation-associated cytokines in patients with AECOPD. |
| T411 |
1386-1557 |
Sentence |
denotes |
The results showed that SFJDC significantly reduced the levels of interleukin-8 (IL-8), TNF-α, CRP, and PCT, and had significant therapeutic efficacy against AECOPD (Yu H. |
| T412 |
1558-1575 |
Sentence |
denotes |
X. et al., 2020). |
| T413 |
1576-1767 |
Sentence |
denotes |
Tiling Wang et al. added SFJDC treatment to conventional treatment in 60 mild and moderate AECOPD patients and compared with 60 patients receiving conventional treatment as the control group. |
| T414 |
1768-1918 |
Sentence |
denotes |
After 1 week, the treatment group had significantly higher arterial blood gas PaO2 than the control group, without any adverse reactions (Wang, 2015). |
| T415 |
1919-2185 |
Sentence |
denotes |
Research showed that treatment of bacterial acute bronchitis and pneumonia with a combination of antibacterial drugs and SFJDC significantly shortened recovery of body temperature, duration of cough and the course of treatment compared with antibacterial drug alone. |
| T416 |
2186-2491 |
Sentence |
denotes |
Chunlan Wang et al. observed that combined use of SFJDC and antibiotics significantly improved body temperature, blood sugar, ALT (glutamate transaminase), AST (aspartate aminotransferase) and other indicators compared with the control group, and patients had a higher oxygen index than the control group. |
| T417 |
2492-2687 |
Sentence |
denotes |
The results suggested that SFJDC had a significant protective function against lung injury, and the mechanism might be related to inhibition of inflammatory response by SFJDC (Wang et al., 2014). |
